Anticoagulation Length in Cancer Associated Thrombosis

• Status: Terminated
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a two year, multicentre, mixed methods feasibility study including a randomised controlled two-arm interventional trial, a nested qualitative study, focus groups and a United Kingdom (UK) wide survey exercise.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cardiff University
• Collaborators: National Institute for Health Research, United Kingdom; Wales Cancer Trials Unit
• Treatments: Calcium heparin; Dalteparin; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

• Receiving LMWH for treatment of CAT for five months

• Locally advanced or metastatic cancer

• Able to self-administer LMWH, or have LMWH administered by a carer

• Able to give informed consent

• Age ≥16 years

Exclusion Criteria:

• Receiving drug other than LMWH for CAT

• Contraindication to anticoagulation

• Fitted with a prosthetic heart valve

• Pregnant and/or lactating females